MIRA Pharmaceuticals (MIRA)

Executive Summary

MIRA Pharmaceuticals is a clinical-stage company developing novel oral analogs of ketamine and marijuana for neurologic and neuropsychiatric disorders. Its lead candidates, Ketamir-2 (oral ketamine analog) and MIRA-55 (oral THC analog), target treatment-resistant depression, pain, and other conditions, aiming to improve bioavailability and therapeutic profiles over existing therapies. The company is currently advancing these programs through Phase 1 trials, with initial data expected to inform dose selection and potential differentiation from competitors like Spravato and synthetic THC drugs. MIRA's technology focuses on molecular modifications to enhance oral absorption and reduce side effects, potentially expanding treatment markets if successfully developed. However, as a small publicly traded company with limited resources, execution risk is significant, and the path to approval requires successful clinical data and regulatory milestones. Conviction is tempered by early-stage status and lack of disclosed clinical results, but the novel approach and large addressable markets warrant attention.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 top-line data for Ketamir-260% success
• Q4 2026Phase 1 top-line data for MIRA-5555% success
• Q1 2027Initiation of Phase 2 trial for lead candidate70% success